CHINA SXT PHARMACEUTICALS-A
SXTCNASDAQTrading Snapshot
- Day Range
- $2.67 – $2.75
- 52-Week Range
- $1.78 – $83,758.40
- Volume
- $2.81B
- Avg Volume
- $1.91B
- Shares Outstanding
- 42.7M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 3.0x
- EPS (TTM)
- $-7.95
- Dividend Yield
- —
- Dilution (1yr)
- +0.0%
Why Investors Own SXTC
- ✓High-growth profile — revenue up +34.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CHINA SXT PHARMACEUTICALS-A
SXTC
StockOtter · stockotter.spaceAbout CHINA SXT PHARMACEUTICALS-A
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company”), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the clo
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
TAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive securities purchase agreement with certain institutio
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 37.4% in June
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC - Get Free Report) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 45,019 shares, a dro